Exploration of phenylpropanoic acids as agonists of the free fatty acid receptor 4 (FFA4): Identification of an orally efficacious FFA4 agonist

Bioorganic and Medicinal Chemistry Letters

Volumn 27, Issue 5, 2017, Pages 1278-1283

  Sparks, Steven M ^a   Aquino, Christopher ^a   Banker, Pierette ^a   Collins, Jon L ^a   Cowan, David ^a   Diaz, Caroline ^a   Dock, Steven T ^a   Hertzog, Donald L ^a   Liang, Xi ^a   Swiger, Erin D ^a   Yuen, Josephine ^a   Chen, Grace ^a   Jayawickreme, Channa ^a   Moncol, David ^a   Nystrom, Christopher ^a   Rash, Vincent ^a   Rimele, Thomas ^a   Roller, Shane ^a   Ross, Sean ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Free fatty acid receptor 1; Free fatty acid receptor 4; GPR120; Phenylpropanoic acid; Type 2 diabetes

Indexed keywords

G PROTEIN COUPLED RECEPTOR 120; GLUCOSE; PHENYLPROPANOIC ACID DERIVATIVE; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; GLUCOSE BLOOD LEVEL; O3FAR1 PROTEIN, MOUSE; PHENYLPROPIONIC ACID DERIVATIVE; PROTEIN BINDING;

AGONIST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; HUMAN; METABOLISM; RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; PHENYLPROPIONATES; PROTEIN BINDING; RATS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85011003357     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2017.01.034     Document Type: Article

References (42)

1. Hue, L., Taegtmeyer, H., The Randle cycle revisited: a new head for an old hat. Am J Endocrinol MeTable 297 (2009), E578–E591.
2. Layden, B.T., Angueira, A.R., Brodsky, M., Durai, V., Lowe, W.L. Jr., Short chain fatty acids and their receptors: new metabolic targets. Transl Res 161 (2013), 131–140.
3. Stoddart, L.A., Smith, N.J., Milligan, G., International union of pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 60 (2008), 405–417.
4. Vangaveti, V., Shashidhar, V., Jarrod, G., Baune, B.T., Kennedy, R.L., Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. Ther Adv Endocrinol MeTable 1 (2010), 165–175.
5. Vinolo, M.A.R., Hirabara, S.M., Curi, R., G-protein-coupled receptors as fat sensors. Curr Opin Clin Nutr Metab Care 15 (2012), 112–116.
6. Yonezawa, T., Kurata, R., Yoshida, K., Murayama, M.A., Cui, X., Hasegawa, A., Free fatty acids-sensing G protein-coupled receptors in drug targeting and therapeutics. Curr Med Chem 20 (2013), 3855–3871.
7. Burns, R.N., Moniri, N.H., Agonism with the omega-3 fatty acids α-linolenic acid and docosahexaenoic acid mediates phosphorylation of both the short and long isoforms of the human GPR120 receptor. Biochem Biophys Res Commun 396 (2010), 1030–1035.
8. Oh, D.Y., Talukdar, S., Bae, E.J., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142 (2010), 687–698.
9. Oh, D.Y., Walenta, E., Akiyama, T.E., et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med 20 (2014), 942–947.
10. Garrido, D.M., Corbett, D.F., Dwornik, K.A., et al. Synthesis and activity of small molecule GPR40 agonists. Bioorg Med Chem Lett 16 (2006), 1840–1845.
11. McKeown, S.C., Corbett, D.F., Goetz, A.S., et al. Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor. Bioorg Med Chem Lett 17 (2007), 1584–1589.
12. Briscoe, C.P., Peat, A.J., McKeown, S.C., et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 148 (2006), 619–628.
13. Briscoe, C.P., Tadayyon, M., Andrews, J.L., et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278 (2003), 11303–11311.
14. Itoh, Y., Kawamata, Y., Harada, M., et al. Free fatty acids regulate insulin secretion from pancreatic Î2 cells through GPR40. Nature 422 (2003), 173–176.
15. Burant, C.F., Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes. Diabetes Care 36 (2013), S175–S179.
16. Choi, Y.J., Shin, D., Lee, J.Y., G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes. Arch Pharmacal Res, 2013 Ahead.
17. Feng, X.T., Leng, J., Xie, Z., Li, S.L., Zhao, W., Tang, Q.L., GPR40: a therapeutic target for mediating insulin secretion (review). Int J Mol Med 30 (2012), 1261–1266.
18. Kaku, K., Fasiglifam as a new potential treatment option for patients with type 2 diabetes. Expert Opin Pharmacother 14 (2013), 2591–2600.
19. Poitout, V., Lin, D.C.H., Modulating GPR40: therapeutic promise and potential in diabetes. Drug Discovery Today 18 (2013), 1301–1308.
20. Ichimura, A., Hirasawa, A., Poulain-Godefroy, O., et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483 (2012), 350–354.
21. Mo, X.L., Wei, H.K., Peng, J., Tao, Y.X., Free fatty acid receptor GPR120 and pathogenesis of obesity and type 2 diabetes mellitus. Prog Mol Biol Transl Sci 114 (2013), 251–276.
22. Talukdar, S., Olefsky, J.M., Osborn, O., Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 32 (2011), 543–550.
23. Hirasawa, A., Tsumaya, K., Awaji, T., et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11 (2005), 90–94.
24. Gotoh, C., Hong, Y.H., Iga, T., et al. The regulation of adipogenesis through GPR120. Biochem Biophys Res Commun 354 (2007), 591–597.
25. Miyauchi, S., Hirasawa, A., Iga, T., et al. Distribution and regulation of protein expression of the free fatty acid receptor GPR120. Naunyn-Schmiedeberg's Arch Pharmacol 379 (2009), 427–434.
26. Parker, H.E., Habib, A.M., Rogers, G.J., Gribble, F.M., Reimann, F., Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52 (2009), 289–298.
27. Tanaka, T., Katsuma, S., Adachi, T., Koshimizu, T.A., Hirasawa, A., Tsujimoto, G., Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn-Schmiedeberg's Arch Pharmacol 377 (2008), 523–527.
28. Martin, C., Passilly-Degrace, P., Chevrot, M., et al. Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity. J Lipid Res 53 (2012), 2256–2265.
29. Ichimura, A., Hirasawa, A., Hara, T., Tsujimoto, G., Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis. Prostaglandins Other Lipid Mediators 89 (2009), 82–88.
30. Nguyen, C.A., Akiba, Y., Kaunitz, J.D., Recent advances in gut nutrient chemosensing. Curr Med Chem 19 (2012), 28–34.
31. Oh, D., Lagakos, W.S., The role of G-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity. Curr Opin Clin Nutr Metab Care 14 (2011), 322–327.
32. Im, D.S., Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res 51 (2012), 232–237.
33. Morishita, M., Tanaka, T., Shida, T., Takayama, K., Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J Controlled Release 132 (2008), 99–104.
34. Cornall, L.M., Mathai, M.L., Hryciw, D.H., McAinch, A.J., GPR120 agonism as a countermeasure against metabolic diseases. Drug Discovery Today 19 (2014), 670–679.
35. Halder, S., Kumar, S., Sharma, R., The therapeutic potential of GPR120: a patent review. Expert Opin Ther Pat 23 (2013), 1581–1590.
36. Hara, T., Hirasawa, A., Ichimura, A., Kimura, I., Tsujimoto, G., Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J Pharm Sci 100 (2011), 3594–3601.
37. Hudson, B.D., Shimpukade, B., Mackenzie, A.E., et al. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol Pharmacol 84 (2013), 710–725.
38. Medina, J.C., Houze, J.B., GPR40 (FFAR1) modulators. Annu Rep Med Chem 43 (2008), 75–85.
39. Sparks, S.M., Chen, G., Collins, J.L., et al. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett 24 (2014), 3100–3103.
40. Azevedo, C.M., Watterson, K.R., Wargent, E.T., et al. Non-acidic free fatty acid receptor 4 agonists with antidiabetic activity. J Med Chem 59 (2016), 8868–8878.
41. Lombardo, M., Bender, K., London, C., et al. Discovery of benzofuran propanoic acid GPR120 agonists: from uHTS hit to mechanism-based pharmacodynamic effects. Bioorg Med Chem Lett 26 (2016), 5724–5728.
42. Burgos, C.H., Barder, T.E., Huang, X., Buchwald, S.L., Significantly improved method for the Pd-catalyzed coupling of phenols with aryl halides: understanding ligand effects. Angew Chem Int Ed 45 (2006), 4321–4326.